---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-25-000085"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-19T00:00:20.226755+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways positive Phase 3 COMP005 psilocybin trial meets primary endpoint for TRD

## Summary
- COMP360 25 mg single dose showed MADRS reduction -3.6 vs placebo (p<0.001) at week 6.
- DSMB chair: no new safety findings; no clinically meaningful imbalance in suicidality.
- 258 participants enrolled across 32 US sites; blinded extension to week 26, open-label to 52.
- COMP006 (568 participants) 26-week data expected H2 2026; company plans FDA discussions.
- First pivotal Phase 3 positive; supports regulatory path for COMP360 in treatment-resistant depression.

## SEC filing metadata
- accession: 0001816590-25-000085
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/0001816590-25-000085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-25-000085
- JSON: https://secwatch.observer/filing/0001816590-25-000085.json
- Plain text: https://secwatch.observer/filing/0001816590-25-000085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.